1. Genetic tests
  2. Dihydropyrimidine dehydrogenase deficiency; 5-fluorouracil toxicity - pharmacogenetics (4 variants: DPYD*2A, DPYD*13, c.2846A>T, HapB3) - Pharmacogenetics

Dihydropyrimidine dehydrogenase deficiency; 5-fluorouracil toxicity - pharmacogenetics (4 variants: DPYD*2A, DPYD*13, c.2846A>T, HapB3) - Pharmacogenetics

Genetic test Export to PDF
Full name:
Dihydropyrimidine dehydrogenase deficiency; 5-fluorouracil toxicity - pharmacogenetics (4 variants: DPYD*2A, DPYD*13, c.2846A>T, HapB3) - Pharmacogenetics
Description:

5-fluorouracil (5-FU) toxicity -Dihydropyrimidine dehydrogenase deficiency - DPYD genotyping - Pharmacogenetics
Test type:
Clinical
Test specialty:
Molecular Genetics
Test purpose:
Therapeutic Management
Specimen:
Peripheral (whole) blood on EDTA
Method category:
Targeted variant analysis
Method technique:
Bi-directional Sanger Sequence analysis
Laboratory:
Centrum Medische Genetica - UZ Gent
RIZIV code:
565390-565401
EQA:
  • 2021 Dihydropyrimidine dehydrogenase deficiency GenQA (Genomics Quality Assessment)
Turnaround time (maximum):
2 weeks
Document(s):
Created:
20 Dec 2019 - 14:40
Changed:
24 Jan 2023 - 13:55
URL:
https://www.cmgg.be/nl/zorgverlener/labguide/constitutioneel-genetische-aandoen…